New Business Opportunities in Bio/Pharma,
Medical Devices & Diagnostics

October 2016

Welcome to the October 2016 issue of PharmSource PERISCOPE

This monthly e-newsletter provides valuable insight to sales and marketing professionals who sell goods and services to bio/pharma, medical device or diagnostic companies. It helps you recognize new business opportunities and overcome sales obstacles.

Enjoy the October issue!

The PharmSource Team


PharmSource Lead Sheet
Summary of Global Clinical Pipeline Activity

Lead Type September 2016 YTD 2016
Early Development 155 1067
Late Development 133 1045
Biologic 126 923
Small Molecule 305 2287
Parenteral 124 1026
Oral 112 887
New Financings 76 718
Total Drug Leads 401 3381
Total Device &
Diagnostic Leads
141 1264

*Total leads include acquisitions/alliances, company acquisition/alliances and events.


Pipeline Tip

CymaBay Therapeutics plans to initiate a second Phase II study by the end of 2016 with a lower dosage of MBX-8025 for the treatment of primary biliary cholangitis:

  • Therapeutic Area: Liver disease
  • Dosage Form: Capsule
  • API: Chemical – Normal potency

Get deeper information about the likely upcoming needs of CymaBay, its pipeline, contacts and more in the PharmSource Lead Sheet. If you’re not yet a subscriber, click here to learn more.

Zika Update: Vaccines in Development

by Judy Nanthavong, Senior Research Analyst

On February 1, 2016, the World Health Organization (WHO) declared the cluster of microcephaly cases and neurological disorders a public health emergency of international concern. Both microcephaly and neurological disorders are linked to the Zika virus.

The WHO Emergency Committee also noted that given the absence of population immunity, a major cause for concern is the lack of vaccines and rapid and reliable diagnostic tests.

In order to address the public health emergency of Zika, a number of pharma/biotech companies have… read on

Bio/Pharma Sponsor Spending on In-house Manufacturing Capacity Soars

This data-rich report, Bio/Pharma CapEx Trends 2016, identifies 3 indicators of what’s ahead for your business:

1. Captive capacity remains the largest impediment to faster growth of the contract manufacturing and development industry.

2. Bio/pharma companies have invested over $150 billion for new plant and equipment in the past 5 years.

3. Based on recent capital expenditure trends, learn why bio/pharma companies would rather “make than buy.”


Follow the Money to

Bio/Pharmaceutical Opportunities

Spotlight on Catabasis Pharmaceuticals, Inc.

Catabasis is a U.S. public biopharmaceutical company that focuses on the discovery and development of drugs to treat inflammatory and metabolic conditions. They raised $11.5 million in a secondary public offering

What new business opportunities are most likely to surface from this? We know they plan to use the proceeds to fund clinical trials with CAT-1004, for market development activities and… read on

Follow the Money to

Medical Device & Diagnostic Opportunities

Spotlight on VENITI, Inc.

VENITI is a U.S. private company that develops devices for the management and treatment of venous insufficiency. They raised $25 million in a completion of a Series D venture capital investment.

What new business opportunities are most likely to surface from this? We know they plan to use the proceeds to support clinical trials and regulatory filings for its VICI VENOUS STENT system and… read on

Celebrating 20 Years in Business!

Thank you to our clients, colleagues and friends. We look forward to many more years of successful business together.

PharmSource Lead Sheet

The PharmSource Lead Sheet is the industry’s definitive source for identifying targeted new business opportunities in bio/pharmaceutical companies around the world. Our dedicated research team knows how and where to find fresh, targeted leads, and we have the contact information you need to start the sales process.

Don’t be the last to learn about the latest business development opportunities. If you’re not already using the Lead Sheet, contact us today to schedule a complimentary test-drive.

See for yourself how this resource can be a vital tool for building your brand and growing your market share.

To request a test-drive today, contact Nathaniel Celentano at / 1-703-383-4903, ext. 112 (ET USA).